[go: up one dir, main page]

MX2021010399A - Metodos para tratar enfermedades oculares. - Google Patents

Metodos para tratar enfermedades oculares.

Info

Publication number
MX2021010399A
MX2021010399A MX2021010399A MX2021010399A MX2021010399A MX 2021010399 A MX2021010399 A MX 2021010399A MX 2021010399 A MX2021010399 A MX 2021010399A MX 2021010399 A MX2021010399 A MX 2021010399A MX 2021010399 A MX2021010399 A MX 2021010399A
Authority
MX
Mexico
Prior art keywords
methods
treating ocular
ocular conditions
conditions
treating
Prior art date
Application number
MX2021010399A
Other languages
English (en)
Inventor
James Loudin
Kenneth J Mandell
Douglas Michael Ackermann
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of MX2021010399A publication Critical patent/MX2021010399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos y formulaciones farmacéuticas para tratar afecciones oculares.
MX2021010399A 2016-04-07 2018-10-05 Metodos para tratar enfermedades oculares. MX2021010399A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
MX2021010399A true MX2021010399A (es) 2022-01-18

Family

ID=58549326

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012230A MX385698B (es) 2016-04-07 2017-04-06 Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
MX2021010399A MX2021010399A (es) 2016-04-07 2018-10-05 Metodos para tratar enfermedades oculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018012230A MX385698B (es) 2016-04-07 2017-04-06 Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares

Country Status (19)

Country Link
US (3) US10709707B2 (es)
EP (2) EP3970724A1 (es)
JP (3) JP7090551B2 (es)
KR (2) KR102485299B1 (es)
CN (3) CN109310692B (es)
AU (1) AU2017248276B2 (es)
DK (1) DK3439661T3 (es)
EA (1) EA201892265A1 (es)
ES (1) ES2893126T3 (es)
IL (3) IL299204A (es)
MX (2) MX385698B (es)
MY (1) MY199237A (es)
NZ (1) NZ746468A (es)
PH (1) PH12018502154A1 (es)
PT (1) PT3439661T (es)
SG (1) SG11201808650QA (es)
TW (2) TWI876258B (es)
WO (1) WO2017177024A1 (es)
ZA (1) ZA201807438B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
BR112017008097B1 (pt) 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
CN112638364A (zh) 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合
EP4142734B1 (en) * 2020-04-28 2025-08-20 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
AU2022269610A1 (en) * 2021-05-07 2023-11-23 Oyster Point Pharma, Inc. Co-therapy with vector and nicotinic agonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
DE60209929T2 (de) 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
WO2006100075A2 (en) 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
CA2738806A1 (en) * 2008-10-14 2010-04-22 Psychogenics, Inc. Nicotinic acetylcholine receptor ligands and the uses thereof
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CA3090738C (en) 2008-12-01 2023-06-13 Oyster Point Pharma, Inc. Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
CA2763551A1 (en) * 2009-06-17 2010-12-23 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
JP6162705B2 (ja) 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
EP2786142A4 (en) 2011-11-30 2015-07-22 Diagnostear Ltd DIAGNOSIS OF THE DRY EYE
BR112017008097B1 (pt) * 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
DK3439661T3 (da) * 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser

Also Published As

Publication number Publication date
EA201892265A1 (ru) 2019-04-30
TWI790997B (zh) 2023-02-01
CN109310692B (zh) 2022-01-25
TWI876258B (zh) 2025-03-11
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
IL290069A (en) 2022-03-01
KR102512777B1 (ko) 2023-03-23
US20190201397A1 (en) 2019-07-04
PT3439661T (pt) 2021-09-30
IL290069B2 (en) 2023-05-01
JP2022120125A (ja) 2022-08-17
AU2017248276B2 (en) 2023-07-13
BR112018070497A2 (pt) 2019-01-29
CN114533737B (zh) 2024-05-31
EP3439661A1 (en) 2019-02-13
CA3020170A1 (en) 2017-10-12
EP3439661B1 (en) 2021-08-04
WO2017177024A1 (en) 2017-10-12
CN109310692A (zh) 2019-02-05
JP2024103594A (ja) 2024-08-01
US20200345734A1 (en) 2020-11-05
MX2018012230A (es) 2019-03-28
SG11201808650QA (en) 2018-10-30
IL262102B (en) 2022-03-01
MX385698B (es) 2025-03-18
KR102485299B1 (ko) 2023-01-06
IL262102A (en) 2018-11-29
MY199237A (en) 2023-10-22
KR20190005859A (ko) 2019-01-16
ES2893126T3 (es) 2022-02-08
JP2019513759A (ja) 2019-05-30
TW201737917A (zh) 2017-11-01
IL299204A (en) 2023-02-01
TW202320785A (zh) 2023-06-01
DK3439661T3 (da) 2021-10-18
KR20230010813A (ko) 2023-01-19
JP7090551B2 (ja) 2022-06-24
AU2017248276A1 (en) 2018-11-22
ZA201807438B (en) 2024-09-25
IL290069B1 (en) 2023-01-01
CN114432313A (zh) 2022-05-06
NZ785093A (en) 2024-07-05
US20250000861A1 (en) 2025-01-02
WO2017177024A8 (en) 2018-11-08
CN114533737A (zh) 2022-05-27
EP3970724A1 (en) 2022-03-23
NZ746468A (en) 2023-06-30
ES2893126T8 (es) 2022-05-23

Similar Documents

Publication Publication Date Title
GB2541571A (en) Pharmaceutical compositions
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2024013018A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ZA201807438B (en) Methods of treating ocular conditions
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12019501097A1 (en) Magl inhibitors
EA201791095A1 (ru) Способ лечения рака
ZA201703467B (en) Methods of treating ocular conditions
MX2019005771A (es) Inhibidores de magl.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EP3302382A4 (en) IMPLANT FOR THE TREATMENT OF OCULAR DISEASE
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
EP3500591A4 (en) COMPOSITIONS AND METHODS FOR TREATING BONE-ASSOCIATED DISEASES
EP3402531A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
HK1262958A1 (en) Compositions and methods for treatment of eye diseases